aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Colossal Biosciences, founded with the mission to leverage genetic engineering for de-extinction, aims to revive species like the woolly mammoth, Tasmanian tiger, and dodo. The company envisions reintroducing these species into their natural habitats to restore ecological balance. Their primary focus is on developing hybrid calves of the woolly mammoth by 2028 and launching a thylacine research project to release Tasmanian tiger joeys in Australia. Colossal's innovative approach combines cutting-edge biotechnology with conservation efforts.
Notable figures associated with Colossal Biosciences include prominent geneticists and conservationists who bring expertise and credibility to their ambitious projects. The company has garnered significant attention and investment from leading venture capitalists and biotech investors, underscoring its potential impact. Key achievements include advancements in genetic engineering techniques and successful initial phases of their de-extinction projects. Colossal Biosciences aims to make a profound ecological impact by reviving extinct species and promoting biodiversity.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Genetic Engineering
Technology
Biotech
Tags
GenAI
Model Types
Software, Research
Revenue Type(s)
Consulting
Customer Type(s)
Enterprise, Government
Geographic Exposure
Global
When was Colossal Biosciences founded?
Colossal Biosciences was founded in 2021.
Where is Colossal Biosciences’s headquarters located?
Colossal Biosciences’s headquarters is located in Austin, US.
When was Colossal Biosciences’s last funding round?
Colossal Biosciences’s most recent funding round was for $10.5M (USD) in November 2023.
How many employees does Colossal Biosciences have?
Colossal Biosciences has 165 employees as of Feb 5, 2024.
How much has Colossal Biosciences raised to-date?
As of July 05, 2023, Colossal Biosciences has raised a total of $235.5M (USD) since Nov 13, 2023.
Add Comparison
Total Raised to Date
$235.5M
USD
Last Update Nov 13, 2023
Last Deal Details
$10.5M
USD
Nov 13, 2023
Series Unknown
Total Employees Over Time
165
As of Feb 2024
Colossal Biosciences Address
1401 Lavaca St
unit # 155
Austin,
78701
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts